iressa
英
美
网络 易瑞沙; 吉非替尼; 易瑞莎
双语例句
- Iressa from AstraZeneca and Vectibix from Amgen are among EGFR blockers now available to treat colorectal, lung, breast and other cancers.
阿斯利康公司的Iressa和Amgen公司的Vectibix是目前用于临床治疗结直肠肿瘤、肺癌、乳腺癌和其他肿瘤的EGFR拮抗剂。 - Factors Contributed to Anticancer and Adverse Effects in Advanced Adenocarcinoma of Lung with Iressa
吉非替尼治疗晚期肺腺癌的疗效和毒副作用 - Clinical Study of Iressa in the Treatment for Advanced Non-small Cell Lung Cancer
易瑞沙治疗终末期非小细胞肺癌的临床观察 - Lung neoplasm; Iressa; Toxicity reaction; Treatment outcome.
肺腺癌；易瑞沙；毒副反应；治疗结果。 - Comparison of docetaxel and Iressa in the treatment of non-small-cell lung cancer patients
TP方案和易瑞沙二线治疗非小细胞肺癌的比较 - The effect of Iressa on proliferation of breast cancer cells with different expression state of ER
Iressa对ER表达状态不同的乳腺癌细胞增殖的影响 - IRs of Hep-3B cell xenograft growth were 32.77% in low-dose group and 46.99% in high-dose group;
低剂量组和高剂量组Iressa对Hep-3B肝癌移植瘤的抑瘤率分别为32.77%、46.99%； - Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer
IRESSA治疗晚期难治性非小细胞肺癌的临床研究 - Gefitinib ( Iressa, ZD1839) is a selective EGFR-TK ( epidermal growth factor recep-tor tyrosine kinase) inhibitor.
吉非替尼（gefitinib，Iressa，zD1839）是一种口服选择陛表皮生长因子受体酪氨酸激酶抑制剂。 - In this review, we discussed recent progression in three aspects, including patients 'characteristics and efficacy of IRESSA, the expression of EGFR or its downstream molecules and IRESSA efficacy, and the mutational status of EGFR and IRESSA efficacy.
本文从IRESSA疗效与患者特征、IRESSA疗效与EGFR及其下游因子的表达水平，以及IRESSA疗效与EGFR突变三个方面，将近几年的研究进展综述如下。 - Objective: To evaluate the efficacy of sequential administration of gefitinib ( Iressa) following a response to two to three cycles of chemotherapy in patients with advanced non-small-cell lung cancer ( NSCLC).
目的：评价化疗微效以上序贯给予IRESSA方案治疗晚期非小细胞肺癌（NSCLC）的临床价值。 - Evaluation of Safety and Efficacy of Gefitinib ('Iressa ', Zd1839) as a Treatment for Advanced Non-Small-Cell Lung Cancer
吉非替尼（Iressa，ZD1839）治疗晚期非小细胞肺癌的疗效及安全性评价 - With Iressa as the lead compound, sixteen new compounds which had not been reported in literatures were designed and synthesized and their chemical structures were confirmed by~ 1H-NMR, IR and MS.
以Iressa为先导化合物，设计合成了16个未见文献报道的新化合物。Iressa及其衍生物的化学结构经核磁共振氢谱、红外光谱和质谱确证。